Sermorelin

FDA-approved context Growth Hormone 2 sources

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to naturally produce and release human growth hormone (hGH), making it a subject of research for age-related growth hormone decline, body composition, and vitality.

01Dosing reference

Amount

200-500 mcg/day

Frequency

Once daily, typically administered at night before bed

Cycle

3-6 months on, followed by 1 month off

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GHRH Receptor Binding

Sermorelin binds to the growth hormone-releasing hormone (GHRH) receptors located in the anterior pituitary gland.

Endogenous GH Secretion

Activation of these receptors stimulates the pituitary gland to produce and secrete natural human growth hormone (hGH) in a pulsatile manner.

IGF-1 Elevation

Increased GH levels prompt the liver to produce Insulin-like Growth Factor 1 (IGF-1), which mediates tissue repair, muscle growth, and metabolic benefits.

03Human evidence

Increased growth velocity in children with growth hormone deficiency.

Clinical trials demonstrated that daily subcutaneous injections of Sermorelin effectively promoted linear growth in pediatric patients with idiopathic GH deficiency.

Improved body composition and IGF-1 levels in older adults.

Studies in aging populations showed that Sermorelin administration increased endogenous GH and IGF-1 levels, leading to improvements in lean body mass and skin thickness, though long-term functional outcomes require more research.

04Preclinical evidence

Dose-dependent stimulation of GH release in vitro.

Experiments using isolated pituitary cells demonstrated that Sermorelin effectively and specifically stimulates GH secretion without affecting other pituitary hormones.

Preservation of pulsatile GH secretion patterns.

Animal models showed that unlike continuous exogenous GH administration, Sermorelin enhances the natural, episodic release of GH, which is crucial for optimal receptor sensitivity.

05What is known vs. unknown

Reasonably established

Sermorelin consists of 29 amino acids, representing the functional fragment of the 44-amino acid natural GHRH.
It stimulates the body's own production of growth hormone rather than replacing it directly.
It preserves the natural pulsatile release of GH, which helps prevent receptor downregulation.
It has a very short half-life in the bloodstream, typically requiring daily subcutaneous injections.

Unknowns & limits

The long-term safety and efficacy of continuous Sermorelin use for anti-aging purposes in healthy adults are not fully established.
Optimal dosing protocols to maximize benefits while minimizing potential side effects in non-deficient populations remain debated.

06Safety & regulatory context

Regulatory statusSermorelin acetate was previously FDA-approved (under the brand name Geref) for diagnostic evaluation of pituitary function and for the treatment of pediatric growth hormone deficiency. It was discontinued by the manufacturer for commercial reasons, not due to safety concerns. It is generally considered well-tolerated. Common side effects include injection site reactions (pain, redness, or swelling), flushing, headache, dizziness, and hyperactivity. Because it stimulates natural GH production, it is thought to have a lower risk of overdose or severe side effects compared to exogenous HGH therapy. It is currently available through compounding pharmacies with a valid prescription.

07Compared with Human Growth Hormone (HGH)

Sermorelin vs. Human Growth Hormone (HGH)

Key difference

Sermorelin stimulates the pituitary gland to produce its own natural GH, whereas HGH therapy involves injecting synthetic GH directly into the body.

When researchers discuss each

Researchers discuss Sermorelin when the goal is to restore natural GH pulses and minimize the risk of tachyphylaxis or pituitary suppression. HGH is discussed for profound, direct replacement in cases of severe deficiency where the pituitary cannot produce GH.

08Glossary

GHRH (Growth Hormone-Releasing Hormone)

A hormone produced in the hypothalamus that signals the pituitary gland to release growth hormone.

Pituitary Gland

A small, pea-sized gland at the base of the brain that produces and releases various essential hormones, including growth hormone.

IGF-1 (Insulin-like Growth Factor 1)

A hormone produced primarily by the liver in response to growth hormone, responsible for many of the growth-promoting and anabolic effects in the body.

09Knowledge check

Q1How does Sermorelin primarily differ from exogenous HGH therapy?

Q2What is the primary biological target of Sermorelin?

Q3Which documented limitation about Sermorelin is explicitly noted in the supplied dossier?

Q4According to the dossier's comparison section, in which research scenario is Sermorelin specifically discussed rather than direct HGH therapy?

Q5Which statement best matches the dossier's safety and regulatory description of Sermorelin?

10Sources

More in Growth Hormone

See all

Tesamorelin

Growth Hormone

FDA-approved context

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete growth hormone. It is FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy and is being researched for potential cognitive benefits.

2 mg/day

Hexarelin

Growth Hormone

Human clinical

Hexarelin is a potent, synthetic hexapeptide and growth hormone secretagogue (GHS) that stimulates the release of growth hormone. Research indicates it is one of the strongest GH-releasing peptides available, offering potential benefits for muscle growth, fat loss, and cardiovascular health without significantly increasing appetite.

100-200 mcg per dose

GHRP-6

Growth Hormone

Human clinical

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates the release of endogenous growth hormone from the pituitary gland. Research shows it can increase appetite, promote muscle growth, and aid in fat loss by mimicking the action of ghrelin.

100-300 mcg per injection

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.